Latest - Rivervest - News & Press / Case Studies / Articles

Featured
Case Studies

Allakos: Reining in the Immune System

News & Press

RiverVest’s Tom Melzer Forecasts St. Louis VC, Start-up Growth for 2020

News & Press

Life sciences VC RiverVest Expands Team with New Managing Director and Senior Associate

Featured
Case Studies

InterVene: Medical Device Game-Changer in the Making

News & Press

RiverVest Mourns Passing of Co-Founder Andrew B. Craig III

News & Press

RiverVest Builds Another San Diego Based Biopharma Company

Featured
Case Studies

Lumena: Transformative Medicines for Liver Diseases

News & Press

Sivan Weitzman Joins RiverVest Venture Partners as CFO

News & Press

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Science Fund

Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001 6/23/2020
Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis 6/2/2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio – 4/27/2020
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors. – 4/21/2020
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline – 4/2/2020
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update – 3/12/2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing – 3/2/2020
Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth – 2/19/2020
InterVene, Inc. Wins TCT 2019 Shark Tank Innovation Competition – 9/29/2019
Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease – 2/18/2020
Mirum Pharmaceuticals Announces Pricing of Public Offering – 1/8/2020
Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat – 12/16/2019
Allakos Reports Third Quarter 2019 Financial Results – 11/12/2019
Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome – 10/28/2019
Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia – 09/19/2019
Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients – 9/16/2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia – 9/16/2019
FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications – 9/9/2019
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE) – 8/5/2019
Allakos Announces Upsizing and Pricing of Public Offering of Common Stock – 8/9/2019
Allakos Reports Second Quarter 2019 Financial Results – 8/5/2019
Allakos Announces Proposed Public Offering of Common Stock
Mirum Pharmaceuticals Announces Pricing of Initial Public Offering
InterVene Raises $15 Million in Series B Funding for First Catheter-Based System to Correct Deep Vein Valve Failure
Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases – 5/20/2019